Lymphocytic lymphoma, formally called small lymphocytic lymphoma (SLL), is a slow-growing cancer of white blood cells called B-lymphocytes. It develops primarily in the lymph nodes and spleen rather than the bloodstream. SLL has an 88.8% five-year relative survival rate, making it one of the more manageable blood cancers, though it requires long-term monitoring.
How SLL Relates to CLL
SLL and chronic lymphocytic leukemia (CLL) are considered different manifestations of the same disease by the World Health Organization. The cancer cells in both look identical under a microscope and carry the same genetic markers. The distinction is where those cells accumulate. In CLL, malignant B-cells flood the bloodstream, producing a high white blood cell count. In SLL, those same cells build up in the lymph nodes, spleen, or liver without significantly raising blood counts. Some patients start with SLL and later develop CLL-like features, or vice versa, which is why doctors often refer to the combined entity as CLL/SLL.
Common Symptoms
Many people with SLL have no symptoms at diagnosis. The cancer is often found incidentally during routine bloodwork or a physical exam. When symptoms do appear, they typically develop gradually as the disease progresses.
The most noticeable sign is swollen lymph nodes, which feel like firm, painless lumps under the skin, most often in the neck, armpits, or groin. Other symptoms include unexplained weight loss (10% or more of body weight over six months), drenching night sweats, fevers lasting two weeks or longer without an obvious infection, persistent fatigue, loss of appetite, and pain or fullness in the upper left abdomen from an enlarged spleen. These systemic symptoms, sometimes called “B-symptoms,” signal that the disease is becoming more active.
What Causes It
SLL begins when B-lymphocytes, immune cells that normally produce antibodies to fight infection, undergo genetic changes that cause them to multiply uncontrollably. These abnormal cells accumulate over time because they also resist the normal process of programmed cell death. Chronic stimulation of the immune system may contribute to the initial transformation, essentially pushing these B-cells through repeated rounds of division that increase the chance of a cancer-causing mutation taking hold.
There is no single known cause. Risk increases with age, and most people diagnosed are over 60. A family history of blood cancers raises risk modestly, and men are affected more often than women.
How SLL Is Diagnosed
Diagnosis typically starts with a biopsy of an enlarged lymph node. A pathologist examines the tissue and runs a specialized test called flow cytometry, which identifies specific proteins on the surface of the cancer cells. SLL cells carry a distinctive combination of markers: they test positive for CD5, CD19, and CD23, while showing unusually weak levels of CD20 and certain other surface proteins. This pattern helps distinguish SLL from other lymphomas that can look similar, particularly mantle cell lymphoma, which shares the CD5 marker but lacks CD23.
Blood tests, imaging scans, and sometimes a bone marrow biopsy help determine how far the disease has spread. Genetic testing of the cancer cells can also identify specific chromosomal abnormalities that influence prognosis and treatment decisions.
Staging
SLL and CLL use the Rai staging system, which runs from Stage 0 to Stage IV based on where the disease has spread and how much it affects normal blood cell production:
- Stage 0: High lymphocyte count in the blood only, no swollen lymph nodes or organ enlargement.
- Stage I: High lymphocyte count plus swollen lymph nodes.
- Stage II: Enlarged liver or spleen, with or without swollen lymph nodes.
- Stage III: Anemia develops because the cancer is crowding out healthy cells in the bone marrow.
- Stage IV: Low platelet counts, indicating significant bone marrow involvement.
Stages 0 through II are generally considered low to intermediate risk. Stages III and IV carry higher risk because they reflect the cancer’s interference with the bone marrow’s ability to produce normal blood cells.
Watch and Wait
The majority of people with SLL have early-stage, asymptomatic disease at diagnosis. For these patients, treatment does not begin right away. Instead, doctors follow a strategy called “watch and wait,” which involves regular checkups every few months to monitor blood counts, lymph node size, and symptoms. Starting treatment early in asymptomatic patients has not been shown to improve outcomes, so the goal is to delay therapy and its side effects until the disease genuinely needs to be addressed.
Treatment is triggered when specific thresholds are crossed: lymph nodes growing to 10 centimeters or larger, a rapidly rising lymphocyte count (doubling in under six months), worsening anemia or low platelets from bone marrow failure, significant weight loss, persistent fevers or night sweats, or a spleen that extends six or more centimeters below the rib cage. Meeting any of these criteria signals that the cancer is active enough to warrant therapy.
Treatment Options
When treatment is needed, targeted therapies have largely replaced traditional chemotherapy as the standard approach. The two main drug classes work by blocking different survival signals the cancer cells depend on.
The first class, BTK inhibitors, blocks a protein that cancer cells need to grow and survive. Ibrutinib was the first of these drugs approved, followed by second-generation options like acalabrutinib and zanubrutinib, which tend to cause fewer side effects while maintaining similar effectiveness. These are taken as daily pills, often continuously until the disease progresses or side effects become unmanageable.
The second class targets a protein called BCL-2 that prevents cancer cells from dying on schedule. Venetoclax, the main drug in this category, is highly effective in SLL and can be given for a fixed duration rather than indefinitely. Combining a BTK inhibitor with venetoclax has shown the potential for deeper responses, and clinical trials have demonstrated remarkable results with this pairing, sometimes allowing patients to stop treatment after a set period.
Richter Transformation
A small but serious complication of SLL is Richter transformation, where the slow-growing cancer converts into an aggressive form of lymphoma, most often diffuse large B-cell lymphoma. This occurs in roughly 2 to 10% of patients, at a rate of about 0.5 to 1% per year. Warning signs include rapidly enlarging lymph nodes, sudden worsening of B-symptoms, and sharply rising blood markers. Richter transformation requires prompt, intensive treatment and carries a significantly worse prognosis than standard SLL.
Living With SLL
Because SLL is a chronic condition that many people live with for years, lifestyle factors play a meaningful supporting role alongside medical care. Fatigue is one of the most common and frustrating symptoms, even during watch-and-wait periods.
Moderate exercise has shown surprisingly strong effects. In a small study of people with CLL/SLL, a single 30-minute session on a stationary bike produced a 300% increase in natural killer cells, immune cells that can destroy cancer cells. When researchers tested a CLL treatment drug against blood samples taken after exercise, the drug worked 129% more effectively than in pre-exercise samples. Follow-up research suggests these immune benefits persist in people who exercise regularly. Even gentle activities like walking, yoga, or stretching can help if fatigue makes more vigorous exercise feel impossible.
Relaxation techniques have also shown measurable benefits. A review of 12 studies involving over 1,000 cancer patients found that practices like meditation and deep breathing reduced cancer-related fatigue, depression, anxiety, and sleep disruption. For a disease that may involve years of monitoring and uncertainty, managing stress is not a luxury but a practical part of care.